About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:ATNM
CUSIPN/A
Phone+1-646-6773875
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-187.42%
Return on Assets-146.18%
Miscellaneous
EmployeesN/A
Outstanding Shares110,200,000
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) announced its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.
What price target have analysts set for ATNM?
4 Wall Street analysts have issued 12-month target prices for Actinium Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' share price to reach $4.50 in the next year. View Analyst Ratings for Actinium Pharmaceuticals.
What are Wall Street analysts saying about Actinium Pharmaceuticals stock?
Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (4/5/2018)
- 2. Maxim Group analysts commented, "Actinium presented a poster: A Phase 2 Study of Actinium-225 (225Ac)- Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy"." (12/6/2017)
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 1,205,816 shares, an increase of 46.4% from the March 30th total of 823,593 shares. Based on an average trading volume of 1,147,430 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.1% of the shares of the stock are short sold.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include Tiziana Life Sciences (TILS), Medicure (MPH), Kitrinor Metals (SCYB), Pfenex (PFNX), Oragenics (OGEN), Asterias Biotherapeutics (AST), ProMIS Neurosciences (PMN), Tissue Regenix Group (TRX), Covalon Technologies (COV), Motif (MTFB), Innovation (IPIX), Helix Biopharma (HBP), Ergomed (ERGO), Cardiome Pharma (COM) and InMed Pharmaceuticals (IMLFF).
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Exec. Chairman and Chief Exec. Officer (Age 54)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer and VP of Fin. & Corp. Devel. (Age 32)
- Dr. Dale L. Ludwig, Chief Scientific Officer
- Dr. David Gould M.D., Sr. VP of Corp. Devel. and Corp. Affairs
- Dr. Bernie Cunningham Ph.D., Exec. Director of Clinical Supply Chain & Logistics and Cmc Project Management
Has Actinium Pharmaceuticals been receiving favorable news coverage?
Media headlines about ATNM stock have trended somewhat positive on Wednesday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Actinium Pharmaceuticals earned a daily sentiment score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.34.
How big of a company is Actinium Pharmaceuticals?
Actinium Pharmaceuticals has a market capitalization of $32.44 million.
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Actinium Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 1,223.53%. The high price target for ATNM is $6.00 and the low price target for ATNM is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $4.50 | $4.50 | $6.00 |
| Price Target Upside: | 1,223.53% upside | 1,150.00% upside | 552.17% upside | 721.47% upside |
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Consensus Price Target History
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 3/28/2018 | Maxim Group | Set Price Target | Buy | $3.00 |  |
| 3/14/2018 | B. Riley | Set Price Target | Buy | $3.00 | |
| 10/23/2017 | HC Wainwright | Reiterated Rating | Buy | $6.00 | |
| 10/23/2017 | Roth Capital | Reiterated Rating | Buy | $6.00 | |
| 11/2/2016 | FBR & Co | Reiterated Rating | Buy | $9.00 | |
(Data available from 4/25/2016 forward)
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trading and Institutional Ownership History
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2018 | Sandesh Seth | CEO | Buy | 5,000 | $0.38 | $1,900.00 | | |
| 2/28/2018 | Ajit Shetty | Director | Buy | 22,730 | $0.43 | $9,773.90 | | |
| 8/2/2017 | Nitya G Ray | Insider | Buy | 10,000 | $0.75 | $7,500.00 | 10,000 | |
| 8/2/2017 | Sandesh Seth | CEO | Buy | 33,333 | $0.75 | $24,999.75 | 75,833 | |
| 6/15/2017 | Sandesh Seth | Chairman | Buy | 7,500 | $1.16 | $8,700.00 | 37,500 | |
| 6/15/2017 | Steve O'loughlin | Insider | Buy | 3,500 | $1.17 | $4,095.00 | 3,500 | |
| 12/30/2016 | Sandesh Seth | Insider | Buy | 5,000 | $0.88 | $4,400.00 | 35,000 | |
| 12/12/2016 | Sandesh Seth | Insider | Buy | 5,000 | $0.98 | $4,900.00 | 30,000 | |
| 8/31/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 192,927 | $1.83 | $353,056.41 | 4,878,988 | |
| 8/29/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 50,000 | $1.71 | $85,500.00 | 4,939,490 | |
| 8/16/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 9,468 | $1.72 | $16,284.96 | 4,957,517 | |
| 7/12/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 3,100 | $1.80 | $5,580.00 | 4,962,056 | |
| 7/11/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 21,990 | $1.80 | $39,582.00 | 4,965,856 | |
| 7/6/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 20,840 | $1.81 | $37,720.40 | 5,001,886 | |
| 7/1/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 148,100 | $1.81 | $268,061.00 | 5,140,786 | |
| 6/15/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 33,619 | $1.90 | $63,876.10 | 5,155,986 | |
| 6/2/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 17,790 | $2.01 | $35,757.90 | 5,196,395 | |
| 6/1/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 169,450 | $1.97 | $333,816.50 | 5,358,735 | |
| 5/26/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 40,068 | $1.92 | $76,930.56 | 5,389,745 | |
| 5/25/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 36,400 | $1.90 | $69,160.00 | 5,427,313 | |
| 4/26/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 52,577 | $2.04 | $107,257.08 | 5,502,849 | |
| 4/21/2016 | Sloan-Kettering Cance Memorial | Major Shareholder | Sell | 196,497 | $2.03 | $398,888.91 | 5,652,878 | |
| 4/18/2016 | Sandesh Seth | Chairman | Buy | 15,000 | $1.99 | $29,850.00 | 15,000 | |
| 4/15/2016 | Sergio Traversa | Director | Buy | 3,000 | $2.02 | $6,060.00 | 2,000 | |
| 4/14/2016 | Kaushik J Dave | CEO | Buy | 10,000 | $2.02 | $20,200.00 | 86,500 | |
| 4/14/2016 | Richard I Steinhart | Director | Buy | 2,500 | $2.01 | $5,025.00 | 2,500 | |
(Data available from 1/1/2013 forward)
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Actinium Pharmaceuticals (ATNM) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 24 at 6:38 PM |
 | Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with
www.nasdaq.com - April 18 at 10:27 AM |
 | Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
finance.yahoo.com - April 18 at 10:27 AM |
| Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
finance.yahoo.com - April 11 at 11:02 AM |
| Actinium Pharmaceuticals (ATNM) Short Interest Update
www.americanbankingnews.com - April 11 at 2:04 AM |
| Actinium Pharmaceuticals (ATNM) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 5 at 5:46 PM |
| Maxim Group Reaffirms Buy Rating for Actinium Pharmaceuticals (ATNM)
www.americanbankingnews.com - April 5 at 2:40 PM |
| Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 28 at 11:27 AM |
| Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
finance.yahoo.com - March 28 at 10:25 AM |
| Short Interest in Actinium Pharmaceuticals Inc (ATNM) Declines By 44.2%
www.americanbankingnews.com - March 27 at 1:02 AM |
| Maxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target
www.americanbankingnews.com - March 20 at 10:41 AM |
| Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. Riley
www.americanbankingnews.com - March 17 at 9:58 PM |
| Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 15 at 11:09 AM |
 | Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 3:47 PM |
 | Actinium Pharma (ATNM) Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with R/R AML
www.streetinsider.com - March 14 at 11:28 AM |
| Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients ... - Nasdaq
www.nasdaq.com - March 13 at 3:53 PM |
| Actinium Pharma (ATNM) Announces FDA Clearance of IND For ... - StreetInsider.com
www.streetinsider.com - March 13 at 3:53 PM |
| Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
finance.yahoo.com - March 13 at 11:23 AM |
| Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 91.3%
www.americanbankingnews.com - March 9 at 6:24 PM |
| Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 3:45 PM |
| Actinium Announces $15.4 Million in Expected Gross Proceeds from ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 3:54 PM |
| Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 3:45 PM |
 | Active-Investors: Wired News - Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-B
www.finanznachrichten.de - March 1 at 10:26 AM |
| Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
finance.yahoo.com - February 28 at 10:46 AM |
| Actinium Pharmaceuticals Inc (ATNM) Short Interest Update
www.americanbankingnews.com - February 28 at 1:08 AM |
| Actinium Pharma (ATNM) Announces Activation of Sixteenth Clinical ... - StreetInsider.com
www.streetinsider.com - February 27 at 3:47 PM |
| Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B
finance.yahoo.com - February 27 at 10:58 AM |
| Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and ... - GlobeNewswire (press release)
globenewswire.com - February 26 at 3:41 PM |
 | Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge - Benzinga
www.benzinga.com - February 26 at 3:41 PM |
| Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period - GlobeNewswire (press release)
globenewswire.com - February 22 at 3:46 PM |
| Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
finance.yahoo.com - February 22 at 10:24 AM |
| Actinium Pharmaceuticals Announces Product Showcase and Other ... - GlobeNewswire (press release)
globenewswire.com - February 20 at 3:42 PM |
| Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by B. Riley Analysts
www.americanbankingnews.com - February 16 at 8:46 PM |
| Actinium Pharma (ATNM) Reports Submission of IND For Actimab-A in Combination with CLAG-M for Patients with R/R ... - StreetInsider.com
www.streetinsider.com - February 13 at 5:51 AM |
| Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
finance.yahoo.com - February 13 at 5:51 AM |
| Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
finance.yahoo.com - February 12 at 3:19 PM |
| Short Interest in Actinium Pharmaceuticals Inc (ATNM) Expands By 8.0%
www.americanbankingnews.com - February 9 at 8:06 PM |
| Actinium Appoints Anil Kapur as Chief Commercial Officer to Build ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:18 PM |
| Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
finance.yahoo.com - February 8 at 3:18 PM |
| Actinium Pharmaceuticals Reminds Investors of Record Date for ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:28 AM |
| Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
finance.yahoo.com - February 8 at 5:28 AM |
| Actinium Pharma (ATNM) Reports Trial to Study Actimab-A in ... - StreetInsider.com
www.streetinsider.com - February 6 at 3:19 PM |
| Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
finance.yahoo.com - February 6 at 3:19 PM |
| Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:36 AM |
| Actinium Pharma (ATNM) Announces Rights Offering - StreetInsider.com
www.streetinsider.com - February 2 at 3:19 PM |
| Actinium Pharma (ATNM) Announces Rights Offering
www.streetinsider.com - February 2 at 5:42 AM |
| Actinium Pharmaceuticals Announces Rights Offering
finance.yahoo.com - February 2 at 5:42 AM |
| Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product
finance.yahoo.com - February 1 at 3:18 PM |
| Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 - GlobeNewswire (press release)
globenewswire.com - January 26 at 3:18 PM |
 | Biotech Stocks' Research Reports Released on Ampio Pharma, AmpliPhi Biosciences, Actinium Pharma, and BioPharmX - PR Newswire (press release)
www.prnewswire.com - January 26 at 5:45 AM |
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
